However, most of the currently published studies on IDH inhibitors in IDH-mutated AML patients are single-arm clinical studies and retrospective studies, and individual studies cannot provide strong evidence due to their single-center and small sample size limitations. The gene discussed is IDH1; the disease is acute myeloid leukemia.